Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1986 Mar;45(3):183–189. doi: 10.1136/ard.45.3.183

Differential effects of therapeutic regimens on specific classes of rheumatoid factor.

R M Pope, J Lessard, E Nunnery
PMCID: PMC1001850  PMID: 3954468

Abstract

This study was performed to define further the relationship of circulating IgM and IgG rheumatoid factor to the articular manifestations of rheumatoid arthritis. Patients with substantial clinical improvement (greater than 55%) or no improvement or worsening were chosen for study. Patients were further selected to include those treated with non-steroidal anti-inflammatory drugs (NSAIDs) alone, or NSAIDs plus D-penicillamine or gold. Significant reductions of IgM (p less than 0.001) and IgG (p less than 0.005) rheumatoid factor were seen only in those treated with gold who improved clinically. These observations suggest that in patients experiencing comparable degrees of clinical improvement the simultaneous alterations of circulating IgG and IgM rheumatoid factor observed are dependent upon the therapeutic regimen employed.

Full text

PDF
183

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bluestone R., Goldberg L. S. Effect of D-penicillamine on serum immunoglobulins and rheumatoid factor. Ann Rheum Dis. 1973 Jan;32(1):50–52. doi: 10.1136/ard.32.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cecere F., Lessard J., McDuffy S., Pope R. M. Evidence for the local production and utilization of immune reactants in rheumatoid arthritis. Arthritis Rheum. 1982 Nov;25(11):1307–1313. doi: 10.1002/art.1780251106. [DOI] [PubMed] [Google Scholar]
  3. Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet. 1973 Feb 10;1(7798):275–280. [PubMed] [Google Scholar]
  4. Dixon J. S., Pickup M. E., Lowe J. R., Hallett C., Lee M. R., Wright V. Discriminatory indices of response of patients with rheumatoid arthritis treated with D-penicillamine. Ann Rheum Dis. 1980 Aug;39(4):301–311. doi: 10.1136/ard.39.4.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Egeland T., Lea T., Saari G., Mellbye O. J., Natvig J. B. Quantitation of cells secreting rheumatoid factor of IgG, IgA, and IgM class after elution from rheumatoid synovial tissue. Arthritis Rheum. 1982 Dec;25(12):1445–1450. doi: 10.1002/art.1780251210. [DOI] [PubMed] [Google Scholar]
  6. Goodwin J. S., Ceuppens J. L., Rodriguez M. A. Administration of nonsteroidal anti-inflammatory agents in patients with rheumatoid arthritis. Effects on indexes of cellular immune status and serum rheumatoid factor levels. JAMA. 1983 Nov 11;250(18):2485–2488. [PubMed] [Google Scholar]
  7. Jacoby R. K., Jayson M. I., Cosh J. A. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J. 1973 Apr 14;2(5858):96–100. doi: 10.1136/bmj.2.5858.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jaffe I. A. The effect of penicillamine on the laboratory parameters in rheumatoid arthritis. Arthritis Rheum. 1965 Dec;8(6):1064–1079. doi: 10.1002/art.1780080606. [DOI] [PubMed] [Google Scholar]
  9. Koopman W. J., Miller R. K., Crago S. S., Mestecky J., Schrohenloher R. E. IgA rheumatoid factor: evidence for independent expression at local sites of tissue inflammation. Ann N Y Acad Sci. 1983 Jun 30;409:258–272. doi: 10.1111/j.1749-6632.1983.tb26875.x. [DOI] [PubMed] [Google Scholar]
  10. Kotzin B. L., Strober S., Engleman E. G., Calin A., Hoppe R. T., Kansas G. S., Terrell C. P., Kaplan H. S. Treatment of intractable rheumatoid arthritis with total lymphoid irradiation. N Engl J Med. 1981 Oct 22;305(17):969–976. doi: 10.1056/NEJM198110223051702. [DOI] [PubMed] [Google Scholar]
  11. Lessard J., Nunnery E., Cecere F., McDuffy S., Pope R. M. Relationship between the articular manifestations of rheumatoid arthritis and circulating immune complexes detected by three methods and specific classes of rheumatoid factors. J Rheumatol. 1983 Jun;10(3):411–417. [PubMed] [Google Scholar]
  12. Lorber A., Simon T., Leeb J., Peter A., Wilcox S. Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum. 1978 Sep-Oct;21(7):785–791. doi: 10.1002/art.1780210708. [DOI] [PubMed] [Google Scholar]
  13. McDougal J. S., Hubbard M., McDuffie F. C., Strobel P. L., Smith S. J., Bass N., Goldman J. A., Hartman S., Myerson G., Miller S. Comparison of five assays for immune complexes in the rheumatic diseases. An assessment of their validity for rheumatoid arthritis. Arthritis Rheum. 1982 Oct;25(10):1156–1166. doi: 10.1002/art.1780251003. [DOI] [PubMed] [Google Scholar]
  14. Pope R. M., McDuffy S. J. IgG rheumatoid factor. Relationship to seropositive rheumatoid arthritis and absence in seronegative disorders. Arthritis Rheum. 1979 Sep;22(9):988–998. doi: 10.1002/art.1780220907. [DOI] [PubMed] [Google Scholar]
  15. Pope R. M., McDuffy S. J. IgG rheumatoid factor: analysis of various species of IgG for detection by radioimmunoassay. J Lab Clin Med. 1981 Jun;97(6):842–853. [PubMed] [Google Scholar]
  16. Quismorio F. P., Beardmore T., Kaufman R. L., Mongan E. S. IgG rheumatoid factors and anti-nuclear antibodies in rheumatoid vasculitis. Clin Exp Immunol. 1983 May;52(2):333–340. [PMC free article] [PubMed] [Google Scholar]
  17. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  18. Scott D. G., Bacon P. A., Allen C., Elson C. J., Wallington T. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol. 1981 Jan;43(1):54–63. [PMC free article] [PubMed] [Google Scholar]
  19. Sharp J. T., Lidsky M. D., Duffy J. Clinical responses during gold therapy for rheumatoid arthritis. Changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum. 1982 May;25(5):540–549. doi: 10.1002/art.1780250508. [DOI] [PubMed] [Google Scholar]
  20. Sharp J. T., Lidsky M. D., Duffy J., Thompson H. K., Jr, Person B. D., Masri A. F., Andrianakos A. A. Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis. Relationship of serum gold levels to therapeutic response. Arthritis Rheum. 1977 Jul-Aug;20(6):1179–1187. doi: 10.1002/art.1780200604. [DOI] [PubMed] [Google Scholar]
  21. Srinivasan R., Miller B. L., Paulus H. E. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum. 1979 Feb;22(2):105–110. doi: 10.1002/art.1780220201. [DOI] [PubMed] [Google Scholar]
  22. Trentham D. E., Belli J. A., Anderson R. J., Buckley J. A., Goetzl E. J., David J. R., Austen K. F. Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis. N Engl J Med. 1981 Oct 22;305(17):976–982. doi: 10.1056/NEJM198110223051703. [DOI] [PubMed] [Google Scholar]
  23. Wernick R., Merryman P., Jaffe I., Ziff M. IgG and IgM rheumatoid factors in rheumatoid arthritis. Quantitative response to penicillamine therapy and relationship to disease activity. Arthritis Rheum. 1983 May;26(5):593–598. doi: 10.1002/art.1780260503. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES